Results 241 to 250 of about 595,824 (293)
Advanced Healthcare Materials, EarlyView.The biomimetic nanoplatform IMNP (ETS1 pDNA/PBAE@ITP‐MM) undergoes targeted disassembly at inflammatory vascular sites to release the ETS1 plasmid (pETS1). This release initiates a cascade of effects that inhibit pathogenic pathways and support immune homeostasis. (Abbreviations: EndMT, endothelial‐to‐mesenchymal transition; EC, endothelial cell; TC, T
Feng Zhang +13 more
wiley +1 more source
Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologieopenaire +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Albumin Redhill, a human albumin variant
Clinica Chimica Acta, 1984Albumin Redhill, a variant human albumin with the same C-terminal amino acid as albumin A but with arginine at the N-terminus has been isolated by chromatofocusing from the sera of an English family. Albumin Redhill appears to contain two sites of mutation in its protein chain and is probably a proalbumin.
S, Brand, D W, Hutchinson, D, Donaldson
openaire +2 more sources
Recombinant human serum albumin
Drugs of Today, 2007Human serum albumin (HSA) is responsible for 80% of the colloid osmotic pressure of plasma (25-33 mmHg). Its main clinical use is in maintaining colloid oncotic pressure and increasing circulating plasma volume with the typical dosage in excess of 10 g per dose.
Chuang, Victor, Otagiri, M.
openaire +3 more sources
Phase I Comparability of Recombinant Human Albumin and Human Serum Albumin
The Journal of Clinical Pharmacology, 2005Recombinant human albumin (rHA) is a highly purified animal‐, virus‐, and prion‐free product developed as an alternative to human serum albumin (HSA), to which it is structurally equivalent. The present investigation compared the safety, tolerability, and pharmacokinetics/pharmacodynamics of rHA with HSA.
Dietrich, Bosse +6 more
openaire +2 more sources